Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes

• Published in: Diabetes care Vol. 34; no. 9; pp. 2072 - 2077
• Main Authors: van Poppel, Pleun C.M., Netea, Mihai G., Smits, Paul, Tack, Cees J.
• Format: Journal Article
• Language: English
• Published: Alexandria, VA American Diabetes Association 01.09.2011
• Subjects: acarbose; acetylcholine; Adamantane; Adamantane - analogs & derivatives; Adamantane - therapeutic use; Adult; Aged; analogs & derivatives; Analysis; analysis of variance; Biological and medical sciences; blood; blood flow; Blood vessels; body mass index; Care and treatment; Clinical medicine; cross-over studies; Diabetes; Diabetes Mellitus, Type 2; Diabetes Mellitus, Type 2 - drug therapy; Diabetes. Impaired glucose tolerance; Dilatation; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use; Dosage and administration; drug effects; drug therapy; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Endothelium, Vascular; Endothelium, Vascular - drug effects; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Experiments; Female; Humans; Hypoglycemic Agents; Hypoglycemic Agents - therapeutic use; Male; Medical research; Medical sciences; Metabolic diseases; Metabolites; Metformin; Metformin - therapeutic use; Middle Aged; Miscellaneous; Nitriles; Nitriles - therapeutic use; nitroprusside; noninsulin-dependent diabetes mellitus; Original Research; patients; Public health. Hygiene; Public health. Hygiene-occupational medicine; Pyrrolidines; Pyrrolidines - therapeutic use; Risk factors; Studies; therapeutic use; Treatment outcome; Type 2 diabetes; vasodilation; Vasodilation - drug effects; Veins & arteries; Dipeptidyl-peptidase IV; Endocrinopathy; Type 2 diabetes; Human; Nutrition; Enzyme; Enzyme inhibitor; Metabolic diseases; Endothelium; Peptidases; Improvement; Hypoglycemic agent; Analog; Gliptine derivatives; Hydrolases; Dipeptidyl-peptidase IV inhibitor; Vildagliptin; Endocrinology
• ISSN: 0149-5992; 1935-5548; 1935-5548
• DOI: 10.2337/dc10-2421

To investigate whether the dipeptidyl peptidase-4 inhibitor vildagliptin improves endothelium-dependent vasodilatation in patients with type 2 diabetes. Sixteen subjects with type 2 diabetes (age 59.8 ± 6.8 years, BMI 29.1 ± 4.8 kg/m(2), HbA(1c) 6.97 ± 0.61) on oral blood glucose-lowering treatment were included. Participants received vildagliptin 50 mg b.i.d. or acarbose 100 mg t.i.d. for four consecutive weeks in a randomized, double-blind, cross-over design. At the end of each treatment period, we measured forearm vasodilator responses to intra-arterially administered acetylcholine (endothelium-dependent vasodilator) and sodium nitroprusside (endothelium-independent vasodilator). Infusion of acetylcholine induced a dose-dependent increase in forearm blood flow in the experimental arm, which was higher during vildagliptin (3.1 ± 0.7, 7.9 ± 1.1, and 12.6 ± 1.4 mL ⋅ dL(-1) ⋅ min(-1) in response to three increasing dosages of acetylcholine) than during acarbose (2.0 ± 0.7, 5.0 ± 1.2, and 11.7 ± 1.6 mL ⋅ dL(-1) ⋅ min(-1), respectively; P = 0.01 by two-way ANOVA). Treatment with vildagliptin did not significantly change the vascular responses to sodium nitroprusside. Four weeks' treatment with vildagliptin improves endothelium-dependent vasodilatation in subjects with type 2 diabetes. This observation might have favorable cardiovascular implications.